BLLENREP REMS (Risk Evaluation and Mitigation Strategy)

The BLLENREP REMS is a safety program that manages the risk of ocular toxicity from BLLENREP. The BLLENREP REMS is required by the Food and Drug Administration (FDA) to ensure the potential benefits of BLLENREP outweigh its risks. BLLENREP is only available through the BLLENREP REMS, a restricted distribution program.

Prescribers must become certified in the BLLENREP REMS to prescribe BLLENREP.
LEARN ABOUT PRESCRIBER CERTIFICATION.
LEARN MORE

Healthcare settings must become certified in the BLLENREP REMS to order and dispense BLLENREP.
LEARN ABOUT HEALTHCARE SETTING CERTIFICATION.
LEARN MORE

Patients who are prescribed BLLENREP must be enrolled in the BLLENREP REMS.
LEARN ABOUT PATIENT ENROLLMENT.
LEARN MORE

To learn more about the risks associated with BLLENREP please refer to the Prescribing Information, including Boxed Warning, and the Medication Guide.

To report side effects please contact GlaxoSmithKline at 1-888-825-5249 or FDA at www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).
BLENREP REMS (Risk Evaluation and Mitigation Strategy)

The BLENREP REMS is a safety program that manages the risk of ocular toxicity from BLENREP. The BLENREP REMS is required by the Food and Drug Administration (FDA) to ensure the potential benefits of BLENREP outweigh its risks. BLENREP is only available through the BLENREP REMS, a restricted distribution program.

PREScribers

Prescribers must become certified in the BLENREP REMS to prescribe BLENREP.

LEARN ABOUT PREScriBER CERTIFICATION.

LEARN MORE

HeAlthcare SETTINGS

Healthcare settings must become certified in the BLENREP REMS to order and dispense BLENREP.

LEARN ABOUT HEALTHCARE SETTING CERTIFICATION.

LEARN MORE

PATients

Patients who are prescribed BLENREP must be enrolled in the BLENREP REMS.

LEARN ABOUT PATIENT ENROLLMENT.

LEARN MORE

To learn more about the risks associated with BLENREP please refer to the Prescribing Information, including Boxed Warning, and the Medication Guide.

To report side effects please contact GlaxoSmithKline at 1-888-832-5349 or FDA at www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).
To Become Certified in the BLENREP REMS, Prescribers Must:

1. Complete the training program, which includes reviewing the following educational materials:
   - Prescribing Information
   - Program Overview
   - Education Program for Prescribers

2. Successfully complete and submit the Knowledge Assessment:
   - Online
   - By facsimile at 1-800-635-1044

3. Enroll in the program by completing the Prescriber Enrollment Form and submitting it to the BLENREP REMS:
   - Online
   - By facsimile at 1-800-635-1044

4. The Healthcare Setting where BLENREP will be administered to the patient also needs to be enrolled in the REMS. If this is not at your clinic, please refer to the Healthcare Setting Instructions within the Program Overview. If this is not at your clinic, then reach out to the Healthcare Setting to inform them that they need to enroll in the REMS.

The BLENREP REMS will send confirmation of a prescriber’s enrollment within 2 business days. Including the prescriber’s assigned BLENREP REMS identification number. You will not be able to prescribe BLENREP without completing your certification in the BLENREP REMS Program. If you fail to comply with the BLENREP REMS requirements, you will no longer be able to participate in the BLENREP REMS.

How Do I Enroll a Patient in the BLENREP REMS Program?

1. Counsel your patient using the Patient Guide about:
   - The risk of ocular toxicity and
   - The requirements for monitoring via ophthalmologic exams (visual acuity and slit lamp):
     - At baseline
     - Prior to each dose and
     - Promptly for worsening symptoms

2. Complete and submit the Patient Enrollment Form:
   - Online
   - By facsimile at 1-800-635-1044

The BLENREP REMS will send confirmation of a patient’s enrollment within 2 business days, including the patient’s assigned BLENREP REMS identification number. Patients who are prescribed BLENREP must be enrolled in the BLENREP REMS.

Patient Management:

Before Treatment:
- Assess the patient’s ocular health by consulting an eye care professional to complete visual acuity and slit lamp examinations using the Eye Care Professional Consult Request Form or equivalent.
- Assess the patient’s ophthalmic consult results for appropriateness of initiating treatment. Document and submit to the BLENREP REMS using the Patient Status Form.

During Treatment:
- Assess the patient’s ocular health by consulting an eye care professional to complete visual acuity and slit lamp examinations using the Eye Care Professional Consult Request Form or equivalent.
- Assess the patient’s ophthalmic consult results for corneal adverse reactions, which are based on both corneal examination findings and changes in best-corrected visual acuity (BCVA).
- Manage corneal adverse reactions per Table 1. Dosage Modifications for Corneal Adverse Reactions per the Keratopathy and Visual Acuity (KVA) Scale in the Prescribing Information. With dose reductions or withdrawal of BLENREP until improvement or permanent discontinuation based on severity.
- If continuation of therapy is appropriate, document and submit the Patient Status Form to the BLENREP REMS.
   - Online
   - By facsimile at 1-888-635-1044

Notify the BLENREP REMS if an enrolled patient who has received BLENREP is no longer under your care or has discontinued treatment.
To Become Certified in the BLNREP REMS, Healthcare Settings Must:

1. Designate an Authorized Representative.
2. Review the Prescribing Information, Program Overview and the Education Program for Healthcare Settings.
3. Complete and submit the Healthcare Setting Enrollment Form.
   - Online
   - By fax at 1-866-065-1044

The BLNREP REMS will use confirmation of a Healthcare Setting’s enrollment within 2 business days, including the Healthcare Settings assigned BLNREP REMS certification number. The healthcare setting will not be able to order or dispense BLNREP without completing certification in the BLNREP REMS. If the healthcare setting fails to comply with all BLNREP REMS requirements, the healthcare setting will no longer be able to participate in the BLNREP REMS.

Instructions for Healthcare Settings:

Before administering:
1. Train all relevant staff involved in dispensing and administering BLNREP using:
   - Program Overview
   - Education Program for Healthcare Settings
2. Establish processes and procedures to verify the REMS Checklist is completed and submitted for each patient.
3. Obtain authorization to administer each dose by logging into the BLNREP REMS portal to verify:
   - provider is certified
   - patient is enrolled and authorized to receive BLNREP

After administering, within 5 business days:
1. Complete the dose and drug infusion in the online REMS Checklist and submit it to the REMS within 5 business days of the infusion.
   - Online
   - By fax at 1-866-035-1044

To maintain certification to administer:
1. Have a new authorized representative enroll in the REMS Program by completing the Healthcare Setting Enrollment Form and submitting it to the REMS Program if the authorized representative changes.

At all times:
1. Do not distribute, transfer, sell, or sell BLNREP.
2. Maintain records documenting staff’s completion of REMS training.
3. Maintain records to demonstrate all processes and procedures are in place and being followed.
4. Comply with audits carried out by GlaxoSmithKline or third parties acting on behalf of GlaxoSmithKline to ensure all processes and procedures are in place and are being followed.

*Alternatively, you may contact the BLNREP REMS Coordinating Center at 1-855-206-9183 to verify this information and obtain the authorization to dispense BLNREP.*

Who Can Be an Authorized Representative?

An Authorized Representative at the Healthcare Setting can be a:

- Pharmacist
- Physician
- Director of Healthcare Setting
- Nurse
- Nurse Practitioner
- Physician’s Assistant
- Or any responsible individual in the Healthcare Setting
Patients

A Risk Evaluation and Mitigation Strategy (REMS) is a drug safety program that the U.S. Food and Drug Administration (FDA) can require for certain medicines with serious safety concerns. Drug companies and healthcare providers must take extra steps to make sure the benefits of using the drug are more than the risks. FDA must approve these steps as part of a REMS.

BLENREP has a REMS because of the risk of eye problems. The BLENREP REMS educates patients and doctors about the risks associated with BLENREP. You must be enrolled in the BLENREP REMS to get BLENREP.

How Do I Enroll in the BLENREP REMS and What Is Required of Me?

1. Your healthcare provider will go over this Patient Guide with you to ensure that you understand:
   - Eye problems are common with BLENREP.
   - The risk of eye problems while you are on treatment with BLENREP, which can cause changes to the surface of your eye that can lead to dry eyes, blurred vision, worsening vision, severe vision loss, and corneal ulcer.
   - The need to see an eye specialist to check your eyes:
     - before starting treatment with BLENREP
     - prior to each dose of BLENREP
     - if you have worsening symptoms of eye problems
   - Even if your vision seems fine, it is important that you get your eyes checked during treatment with BLENREP because some changes can happen without symptoms and may only be seen on an eye exam.
   - You should use preservative-free lubricant eye drops at least 4 times per day during treatment with BLENREP as instructed by your healthcare provider.
   - You should use caution when driving or operating machinery as BLENREP may affect your vision.
   - Avoid wearing contact lenses during treatment with BLENREP unless directed by your eye specialist.

2. Your healthcare provider will help you complete and sign the Patient Enrollment Form to enroll you in the BLENREP REMS.
Certified Participant Locator

This may not be an all-inclusive list. Please discuss with your Healthcare Provider.

Please enter a street address, city, state, or ZIP Code you would like to search for.

*Find a Certified Participant near:

*Search Radius:
Within 25 miles

SEARCH
Certified Participant Locator

This may not be an all-inclusive list. Please discuss with your Healthcare Provider.

Please enter a street address, city, state, or ZIP Code you would like to search for.

**CERTIFIED PREScriBERS**  **CERTIFIED HEALTHCARE SETTINGS**

*Find a Certified Participant near:*

12345

*Search Radius:*

Within 25 miles

**SEARCH**

---

To report side effects please contact GlaxoSmithKline at 1-888-825-5249 or FDA at www.fda.gov/medwatch or call 1-888-FDA-1088 (1-888-332-1088).
Certified Participant Locator

This may not be an all-inclusive list. Please discuss with your Healthcare Provider.

Please enter a street address, city, state, or ZIP Code you would like to search for.

**CERTIFIED PRESCRIBERS**

**CERTIFIED HEALTHCARE SETTINGS**

*Find a Certified Participant near: 12345

*Search Radius: Within 25 miles

SEARCH

To report side effects please contact GlaxoSmithKline at 1-888-825-5246
or FDA at www.fda.gov/medwatch
or call 1-800-FDA-1088 (1-800-332-1088).
Resources

Prescribers
- Program Overview
- Education Program for Prescribers
- Knowledge Assessment
- Prescriber Enrollment Form
- Patient Status Form

Healthcare Settings
- Program Overview
- Education Program for Healthcare Settings
- Healthcare Setting Enrollment Form
- REMS Checklist

Patients
- Medication Guide
- Patient Guide
- Patient Enrollment Form

To report side effects please contact GlaxoSmithKline at 1-888-825-6249 or FDA at www.fda.gov/medwatch or call 1-800-FDA-1088 (1-800-332-1088).
Contact Us

PHONE
1-855-209-9188

FAX
1-888-635-1044

HOURS OF OPERATION

Monday - Friday
8:00 AM - 8:00 PM
Eastern Time

To report side effects please contact
GlaxoSmithKline at 1-888-825-5249
or FDA at www.fda.gov/medwatch
or call 1-800-FDA-1088 (1-800-332-1088).

© 2020 GlaxoSmithKline. All rights reserved.
This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

MARC R THEORET
08/05/2020 06:52:09 PM